Clinical evidence and medical strategy from Phase IIIa onward
S&P · Medical, Market Access & Evidence
Evidence creates value when it supports a relevant decision.
S&P connects medical and scientific quality with market, stakeholder, and reimbursement reality. The focus is the strategic interpretation of evidence and its translation into value proposition, medical strategy, market access, and implementation.
Medical, Market Access & Evidence
Medical and evidence scope
Medical affairs and cross-functional interfaces
Real world evidence and noninterventional evidence in strategic context
Value proposition, payer research, and market access strategy
Safety, medical information, and medical writing interfaces
Evidence must travel through access, adoption, and use
Evidence creates value only when it moves successfully through demonstration, enablement, adoption, and sustained use.
Clinical development, value communication, regulatory and payer requirements, stakeholder confidence, and practical access conditions must therefore be connected.
What the figure means for management
Access is the outcome of an integrated value journey, not a final administrative step. Weak transitions can destroy accumulated value even at a late stage.
Concrete S&P contribution
S&P identifies where evidence, narrative, stakeholder confidence, or implementation capability must be strengthened and assigns an owner and early indicator to every transition.
Medical, Market Access & EvidenceDiscuss a medical or access question
Focus and service boundary
Our strongest market access focus is Germany. International positions are developed on a project-specific basis and with appropriate local expertise.
Boundary
S&P does not replace regulatory, legal, or specialized technical advice and does not provide operational study monitoring.